Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis

Katherine Newhall-Perry, K Newhall-Perry, Newhall-Perry K, L Holloway, Holloway L, Leah Holloway, Osburn L, L Osburn, Linda D. Osburn, S E Monroe, Monroe SE, Scott E. Monroe, LeRoy Heinrichs, Heinrichs L, L Heinrichs, M Henzl, Milan R. Henzl, Henzl M, Robert Marcus, R Marcus, Marcus R
American Journal of Obstetrics and Gynecology · 1995 · vol. 173(3) , pp. 824–829 · doi:10.1016/0002-9378(95)90348-8 · PMID:7573251 · W2020472236
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

This study investigated how a GnRH agonist impacts calcium and parathyroid hormone levels, along with bone turnover markers, in women diagnosed with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveOur purpose was to investigate the effects of nafarelin on bone turnover and mass (bone mineral density, in grams per square centimeter) in women with endometriosis.Study designWe monitored 22 young women with endometriosis during and 6 months after 6 months of nafarelin treatment. We compared the bone mineral density status of these women with that of healthy controls undergoing sequential bone mineral density measurement.ResultsSubjects had a 2.2% loss in L2-4 bone mineral density by 6 months, increasing 3 months later to 3% and returning toward baseline by 6 months after treatment. Radius bone mineral density did not change in the treatment group. Bone mineral density did not change in controls. Serum and urinary calcium levels rose during treatment. Hydroxyproline excretion increased and remained elevated 6 months after treatment. A rise in serum osteocalcin persisted 3 months after therapy but normalized by 6 months.ConclusionsBone mineral density deficits with nafarelin are reversible. Increased bone turnover persists 6 months beyond treatment, demonstrating the need for careful monitoring of women receiving prolonged or repeated treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone and Bones Calcium Endometriosis Gonadotropin-Releasing Hormone Nafarelin Parathyroid Hormone Adult Bone and Bones Bone Density Bone Density Bone Remodeling Bone Remodeling Calcitriol Calcitriol Calcium Calcium Calcium Endometriosis Female Gonadotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (22)

Cited by (2)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:13.665691+00:00
License: CC0 · commercial use OK